Figure 1. Photograph of the BabyLux device ready for clinical testing at the Rigshospitalet, Copenhagen (Denmark).
Metabolism and Blood Flow for Neotnatology). 3 With this device, we aim to provide neonatologists with a robust, integrated system for the prevention of neurological damage that is caused by the lack of oxygenation in the brain. After conducting two years of laboratory testing, our clinical protocol was approved by the local ethics committee and our study was accepted by the Danish Medical Agency and the Italian Ministry of Health. We were thus able to begin clinical validation of our system in June 2016, at the Rigshospitalet in Copenhagen, Denmark (see Figure 1 ). We hope that BabyLux will provide physicians with a new monitoring system to guide therapeutic interventions and clinical decisions during the first days of life (when most brain problems tend to occur).
In our system, we use a number of photonic technologies, e.g., diffuse correlation spectroscopy (DCS) 4 and time-resolved near-IR spectroscopy (TRS). 5 For these processes, we rely on an optical fiber probe (see Figure 2 ) to illuminate the scalp of the baby with a very low-power beam and to obtain information from
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deep within the brain (the cortical region). The tool is easy to operate and can be brought to the bedside, which means that it enables prompt measurements and reactions. Our approach also involves placing a small sensor on the baby's head just a few minutes after birth so that cerebral oxygenation and hemodynamics can be monitored. The sensor is then kept on the baby continuously so that measurements can be obtained repeatedly (especially if conditions are critical). The data from BabyLux can be analyzed online with the use of dedicated software. In this way, immediate feedback is available to physicians and nurses. In time, this information will also be post-processed to investigate possible correlations with other parameters that are measured during clinical routines.
We have made a number of significant changes and improvements to the design of our device over time (i.e., during the laboratory phase). For instance, we have enhanced the associated safety procedures and have optimized both the TRS and DCS modules. We have also fine-tuned the hardware and software to ensure that they passed multiple tests.
We will also conduct a second BabyLux study at Ospedale Maggiore Policlinico in Milan (Italy), starting in late September 2016. This trial will be a critical test of the validity of our device. In particular, we will examine the use of the system when the sensor is placed on the head of a baby who is unstable. This represents a critical phase of illness, when adjustments to respiratory and circulatory treatments have to be considered and implemented. During this trial phase we will study three groups of infants: 20 full-term newborn infants (immediately after delivery by cesarean section), 20 preterm infants (when their respirator is adjusted to normalize the partial pressure of carbon dioxide in the blood), and 20 unstable newborn infants (during a 24-hour period).
In summary, we have developed a new neonatal tool-known as BabyLux-to help prevent neurological damage in preterm babies (caused by a lack of oxygenation in the brain). The main goal of our project has been to bridge the gap between research and industry, by addressing a specific need that affects both children and society as a whole. After two years of laboratory tests, we are currently conducting a clinical trial in Denmark and Italy. We plan to deliver the first results at a public conference in Milan, in December 2016. 6 The 
